| Title |
Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO)
|
|---|---|
| Published in |
Annals of Hematology, April 2014
|
| DOI | 10.1007/s00277-014-2086-0 |
| Pubmed ID | |
| Authors |
Olaf Penack, Carolin Becker, Dieter Buchheidt, Maximilian Christopeit, Michael Kiehl, Marie von Lilienfeld-Toal, Marcus Hentrich, Marc Reinwald, Hans Salwender, Enrico Schalk, Martin Schmidt-Hieber, Thomas Weber, Helmut Ostermann |
| Abstract |
Sepsis is a major cause of mortality during the neutropenic phase after intensive cytotoxic therapies for malignancies. Improved management of sepsis during neutropenia may reduce the mortality of cancer therapies. Clinical guidelines on sepsis treatment have been published by others. However, optimal management may differ between neutropenic and non-neutropenic patients. Our aim is to give evidence-based recommendations for haematologist, oncologists and intensive care physicians on how to manage adult patients with neutropenia and sepsis. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 50% |
| Kuwait | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 220 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 3 | 1% |
| Colombia | 1 | <1% |
| Germany | 1 | <1% |
| Sweden | 1 | <1% |
| Unknown | 214 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 30 | 14% |
| Researcher | 28 | 13% |
| Student > Bachelor | 27 | 12% |
| Student > Postgraduate | 23 | 10% |
| Other | 20 | 9% |
| Other | 54 | 25% |
| Unknown | 38 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 110 | 50% |
| Nursing and Health Professions | 14 | 6% |
| Agricultural and Biological Sciences | 12 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 5% |
| Biochemistry, Genetics and Molecular Biology | 6 | 3% |
| Other | 16 | 7% |
| Unknown | 51 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 March 2023.
All research outputs
#4,500,570
of 24,761,242 outputs
Outputs from Annals of Hematology
#194
of 2,348 outputs
Outputs of similar age
#41,710
of 232,915 outputs
Outputs of similar age from Annals of Hematology
#2
of 29 outputs
Altmetric has tracked 24,761,242 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,348 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 232,915 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.